• Placement of new shares to eligible institutional, sophisticated or professional investors
• Non-renounceable entitlement offer of new shares to eligible shareholders
• Raising funds to advance development of neurodegenerative treatments

Neurizon Therapeutics Limited (ASX: NUZ) has announced an equity raising, comprising a placement of new fully paid ordinary shares to certain eligible institutional, sophisticated or professional investors, and a non-renounceable entitlement offer of new shares to eligible shareholders. The funds raised will be used to advance the development of Neurizon's treatments for neurodegenerative diseases. The placement and entitlement offer are not underwritten, and the Company reserves the right to withdraw or vary the offer without notice. Morgans Corporate Limited is acting as placement agent and lead manager and bookrunner for the offer. The directors of the Company reserve the right to issue any shortfall shares from the entitlement offer to new investors or existing shareholders within 3 months of the close of the offer. The allocation of shortfall shares will be at the Company's discretion, considering factors such as the desire for an informed and active trading market, a wide spread of shareholders, and the size and type of funds under management of particular investors. The presentation contains important notices and disclaimers, including that it is for informational purposes only and not a prospectus or offer document, and that the Company makes no representations or warranties as to the accuracy or completeness of the information provided.